Vulpius K, Höh H, Lange H, Maercker W, Rühle H
Augenklinik im Klinikum Neubrandenburg.
Ophthalmologe. 1996 Apr;93(2):149-53.
In central retinal arterial occlusion systemic fibrinolytic therapy can involve a variety of serious complications. The local application of a fibrinolytic agent close to the embolus by means of a femoral catheter should reduce the rate of complications. We therefore present the results of a preliminary study of nine consecutive patients treated with rt-PA via transcutaneous femoral catheter.
From October 1993 to January 1994, nine patients ranging in age from 50 to 83 years who had central retinal occlusion were treated with rt-PA. The latency from the onset of the symptoms to the beginning of the therapy was 10-37 h. A catheter was placed via the femoral artery, the tip being located either at the common carotid artery or at the internal carotid artery or at the internal carotid artery. A continuous infusion containing 10 micrograms (ACTILYSE (rt-PA) was given over 2 h. Thereafter, each patient received 7000 IU heparin sulfate 4 times daily for 3 days and 1200 micrograms pentoxifylline i.v. daily for 10 days. On discharge, permanent therapy with salicylic acid (100 micrograms) was prescribed. The patients have been followed up for up to 18 months so far.
In five of eight patients an improvement of central visual acuity was observed. It changed from perception of hand movement only to 12/20 in three patients. In two of these patients visual acuity had continued to improve after 6-9 months, to 16/20 and 20/20. In one patient visual acuity fell to 6/20 because of progression of ischemic ophthalmopathy. In our patients visual acuity could still be improved even 27 h after arterial occlusion.
A low incidence of complications and the good effect on thrombolysis support the local rt-PA therapy. Good interdisciplinary cooperation is required. Patients must be referred for this therapy as early as possible.
在视网膜中央动脉阻塞时,全身纤溶疗法可能会引发多种严重并发症。通过股动脉导管在栓子附近局部应用纤溶药物应能降低并发症发生率。因此,我们展示了一项对9例连续患者经皮股动脉导管注射rt - PA的初步研究结果。
1993年10月至1994年1月,9例年龄在50至83岁之间的视网膜中央阻塞患者接受了rt - PA治疗。症状出现至治疗开始的潜伏期为10 - 37小时。通过股动脉放置导管,导管尖端位于颈总动脉、颈内动脉或颈内动脉处。在2小时内持续输注含10微克(阿替普酶(rt - PA))的溶液。此后,每位患者每天接受4次7000国际单位硫酸肝素,共3天,以及每天静脉注射1200微克己酮可可碱,共10天。出院时,开具水杨酸(100微克)的长期治疗处方。到目前为止,患者已接受长达18个月的随访。
在8例患者中的5例观察到中心视力有所改善。3例患者的视力从仅能感知手动提高到了12/20。其中2例患者在6 - 9个月后视力持续改善,达到了16/20和20/20。1例患者因缺血性眼病进展,视力降至6/20。在我们的患者中,即使在动脉阻塞27小时后,视力仍可改善。
并发症发生率低以及溶栓效果良好支持局部rt - PA治疗。需要良好的多学科合作。患者必须尽早转诊接受此治疗。